Literature DB >> 11997664

The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide.

J Yi1, F Gao, G Shi, H Li, Z Wang, X Shi, X Tang.   

Abstract

Though reactive oxygen species (ROS) has been noticed to be involved in arsenic trioxide (As(2)O(3))-induced apoptosis of tumor cells, its role in apoptosis signaling remained to be elucidated. The objective of this work was to explore the association of the inherent cellular ROS level with the susceptibility of the tumor cells to apoptosis induction by As(2)O(3). Low concentration of As(2)O(3) was administered to cultured leukemic cell lines NB4, U937, HL60 and K562. The difference in apoptotic sensitivity was displayed among four cell types. ROS probes were incubated with the cells in the absence of As(2)O(3), and ROS was thus quantified relatively by flow cytometry. We manifested, in four cell types, the inherently existed difference in whole ROS quantity, and a positive correlation between the inherent ROS level and their apoptotic sensitivity to As(2)O(3). Furthermore, by interference using a ROS producer, we demonstrated that an elevation of ROS level would sensitize the cells to As(2)O(3)-induced apoptosis. The results of the present work suggested that the inherent ROS level might be determinative in tumor cells for their apoptotic susceptibility to As(2)O(3).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11997664     DOI: 10.1023/a:1015331229263

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  15 in total

1.  Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide.

Authors:  Liu Liu; Chen Chen; Wei Gong; Yuanjing Li; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-08-16       Impact factor: 4.030

2.  Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms.

Authors:  Savita Bhalla; Leo I Gordon; Kevin David; Sheila Prachand; Amareshwar T K Singh; Shuo Yang; Jane N Winter; Dongsheng Guo; Thomas O'Halloran; Leonidas C Platanias; Andrew M Evens
Journal:  Br J Haematol       Date:  2010-04-16       Impact factor: 6.998

Review 3.  ROS-modulated therapeutic approaches in cancer treatment.

Authors:  Muhammad Hassan Raza; Sami Siraj; Abida Arshad; Usman Waheed; Fahad Aldakheel; Shatha Alduraywish; Muhammad Arshad
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-24       Impact factor: 4.553

Review 4.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

5.  Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.

Authors:  Megan Brown; Marcia Bellon; Christophe Nicot
Journal:  Blood       Date:  2006-10-31       Impact factor: 22.113

6.  Variability in sensitivity to arsenite does not correlate with arsenic accumulation rate in normal human lymphoblasts.

Authors:  Ping Li; Ahmed N Uddin; Zijuan Liu; Rita Mukhopadhyay; Elena V Komissarova; Barry P Rosen; Toby G Rossman
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

7.  Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis.

Authors:  Jun Cai; Xin Niu; Yuying Chen; Qingshen Hu; Guiying Shi; Huacheng Wu; Jian Wang; Jing Yi
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

8.  Rituximab sensitizes a Burkitt lymphoma cell line to cell killing by X-irradiation.

Authors:  Min Fengling; Liu Fenju; Wen Wanxin; Zhai Lijia; Tong Jiandong; Wang Zu; Yuan Xin; Gao Qingxiang
Journal:  Radiat Environ Biophys       Date:  2009-08-04       Impact factor: 1.925

9.  MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.

Authors:  Mirna Golemovic; Alfonso Quintás-Cardama; Taghi Manshouri; Nada Orsolic; Hatice Duzkale; Mary Johansen; Emil J Freireich; Hagop Kantarjian; Ralph A Zingaro; Srdan Verstovsek
Journal:  Invest New Drugs       Date:  2009-05-26       Impact factor: 3.850

10.  New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers.

Authors:  Kamil Wolyniec; Dennis A Carney; Sue Haupt; Ygal Haupt
Journal:  Front Oncol       Date:  2013-05-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.